Switch to:
More From Other Websites
Actelion Is a Perfect Fit for Sanofi, but Probably Too Expensive: Exane BNP Dec 07 2016
Sanofi May Battle Johnson & Johnson For European Biotech Actelion Dec 06 2016
Sanofi SA (ADR) (SNY) Could Challenge Johnson & Johnson (JNJ) Bid For Actelion Ltd (ALIOF) Dec 06 2016
Big Pharma, Short on Blockbusters, Outsources the Science Dec 06 2016
Sanofi Said to Weigh Actelion Bid Challenging J&J Dec 06 2016
Sanofi Said to Weigh Actelion Bid Challenging J&J Dec 06 2016
Stocks Open Slightly Lower; Boeing Dips On Trump Tweet Dec 06 2016
5 Things You Must Know Before the Market Opens Tuesday Dec 06 2016
Sanofi Must Pick Its Battle Dec 06 2016
European Stocks Slip Lower, Italy Gains in Mixed Start to Trading Dec 06 2016
Actelion Surges on Report of Sanofi Challenge to J&J Takeover Bid Dec 06 2016
Sanofi exploring bid for Actelion amid J&J talks - Bloomberg Dec 05 2016
Sanofi exploring bid for Actelion amid J&J talks - Bloomberg Dec 05 2016
Sanofi to Explore Counterbid for Actelion Amid J&J Talks Dec 05 2016
12:51 pm Sanofi initiates the ICARIA-MM Phase III trial of isatuximab after preseting prelim results... Dec 05 2016
Sanofi Genzyme Announces Start of Phase III Study of Isatuximab for Relapsed and Refractory Multiple... Dec 05 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK